Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 4
2012 2
2013 7
2014 12
2015 12
2016 9
2017 4
2018 15
2019 13
2020 19
2021 12
2022 14
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Lu Z, et al. Among authors: zaanan a. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. BMJ. 2022. PMID: 35440464 Free PMC article. Clinical Trial.
Small Bowel Adenocarcinoma.
Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR. Aparicio T, et al. Among authors: zaanan a. Gastroenterol Clin North Am. 2016 Sep;45(3):447-57. doi: 10.1016/j.gtc.2016.04.004. Gastroenterol Clin North Am. 2016. PMID: 27546842 Review.
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR. Soularue É, et al. Among authors: zaanan a. Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3. Bull Cancer. 2015. PMID: 25744576
Treatment of gastric adenocarcinoma: A rapidly evolving landscape.
Taieb J, Bennouna J, Penault-Llorca F, Basile D, Samalin E, Zaanan A. Taieb J, et al. Among authors: zaanan a. Eur J Cancer. 2023 Dec;195:113370. doi: 10.1016/j.ejca.2023.113370. Epub 2023 Oct 17. Eur J Cancer. 2023. PMID: 37948843 Free article. Review.
[Immunotherapy in advanced gastric cancer].
Zaanan A. Zaanan A. Bull Cancer. 2022 Oct;109(10):1066-1072. doi: 10.1016/j.bulcan.2022.07.002. Epub 2022 Aug 30. Bull Cancer. 2022. PMID: 36055806 Review. French.
Colorectal Cancer: Why Does Side Matter?
Gallois C, Pernot S, Zaanan A, Taieb J. Gallois C, et al. Among authors: zaanan a. Drugs. 2018 Jun;78(8):789-798. doi: 10.1007/s40265-018-0921-7. Drugs. 2018. PMID: 29790124 Review.
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC, Pallet N, Boige V, Ciccolini J, Chouchana L, Barin-Le Guellec C, Zaanan A, Narjoz C, Taieb J, Thomas F, Loriot MA; Francophone Network of Pharmacogenetics (RNPGx) and the French Clinical Oncopharmacology Group (GPCO)-UNICANCER. Etienne-Grimaldi MC, et al. Among authors: zaanan a. Eur J Cancer. 2023 Mar;181:3-17. doi: 10.1016/j.ejca.2022.11.028. Epub 2022 Dec 9. Eur J Cancer. 2023. PMID: 36621118 Review.
MSI colorectal cancer, all you need to know.
Flecchia C, Zaanan A, Lahlou W, Basile D, Broudin C, Gallois C, Pilla L, Karoui M, Manceau G, Taieb J. Flecchia C, et al. Among authors: zaanan a. Clin Res Hepatol Gastroenterol. 2022 Nov;46(9):101983. doi: 10.1016/j.clinre.2022.101983. Epub 2022 Jun 19. Clin Res Hepatol Gastroenterol. 2022. PMID: 35732266 Review.
120 results